knowledge -WSS

knowledge

author：explore 2025-10-02 22:56:40 - browse：4

Blood samples — Marion Berard/AFP/GettyImages

With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is bracing for the crush.

Based on their ability to slow cognitive decline, the Eisai/Biogen drug Leqembi won full approval from the FDA this month, and donanemab by Eli Lilly could be approved by year end. Clinicians now have to decide which patients are most suitable for treatment, which means better Alzheimer’s tests need to be developed.

“There’s going to be capacity issues because there’s just not enough neurologists in the world to treat this pool of patients with Alzheimer’s disease at the moment,” said Mark Stearman, a senior international product manager at Roche focusing on Alzheimer’s diagnostics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： ACIP vaccine advisory panel sees its vacancies filled

entertainment

WSS

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Why don't Americans have at

Doctors on social media are being harassed and cyberbullied

ASCO: Palliative care found as helpful given virtually as in person

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Cord blood banking comes at a high cost to babies

Wikipedia

knowledge

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

Change Healthcare can notify patients about the breach, HHS says

How to save PrEP access — and even expand it

Too many hospitalized Covid

Duchenne breakthrough therapy leaves behind pioneering families

ASCO: AstraZeneca says CAR

Medicare details structure of new drug price negotiation program

Change Healthcare can notify patients about the breach, HHS says

Moonlake's readout produced a cash windfall. Risks remain

Resistance to opioid

knowledge

Ebola vaccine can save some who are already sick, per new study

Congress might make insulin pumps more accessible to the blind

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

hotspot

hotspot

entertainment

leisure time